Heng DYC - Search Results

1

First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience.

Lalani AA, Li H, Heng DYC, Wood L, Kalirai A, Bjarnason GA, Sim HW, Kollmannsberger CK, Kapoor A, Hotte SJ, Vanhuyse M, Czaykowski P, Reaume MN, Soulieres D, Venner P, North S, Basappa NS. Lalani AA, et al. Among authors: heng dyc. Can Urol Assoc J. 2017 Mar-Apr;11(3-4):112-117. doi: 10.5489/cuaj.4398. Can Urol Assoc J. 2017. PMID: 28515811 Free PMC article.

2

A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer.

Heng DY, Chi KN, Murray N, Jin T, Garcia JA, Bukowski RM, Rini BI, Kollmannsberger C. Heng DY, et al. Cancer. 2009 Feb 15;115(4):776-83. doi: 10.1002/cncr.24051. Cancer. 2009. PMID: 19127560 Free article.

3

State-of-the-art treatment of metastatic renal cell carcinoma.

Heng DY, Kollmannsberger C. Heng DY, et al. Curr Oncol. 2009 May;16 Suppl 1(Suppl 1):S16-23. doi: 10.3747/co.v16i0.407. Curr Oncol. 2009. PMID: 19478897 Free PMC article.

4

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK. Heng DY, et al. J Clin Oncol. 2009 Dec 1;27(34):5794-9. doi: 10.1200/JCO.2008.21.4809. Epub 2009 Oct 13. J Clin Oncol. 2009. PMID: 19826129

5

Sunitinib.

Heng DY, Kollmannsberger C. Heng DY, et al. Recent Results Cancer Res. 2010;184:71-82. doi: 10.1007/978-3-642-01222-8_6. Recent Results Cancer Res. 2010. PMID: 20072832 Review.

6

The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.

Choueiri TK, Xie W, Kollmannsberger C, North S, Knox JJ, Lampard JG, McDermott DF, Rini BI, Heng DY. Choueiri TK, et al. J Urol. 2011 Jan;185(1):60-6. doi: 10.1016/j.juro.2010.09.012. Epub 2010 Nov 12. J Urol. 2011. PMID: 21074201

7

Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy.

Heng DY, Xie W, Bjarnason GA, Vaishampayan U, Tan MH, Knox J, Donskov F, Wood L, Kollmannsberger C, Rini BI, Choueiri TK. Heng DY, et al. Cancer. 2011 Jun 15;117(12):2637-42. doi: 10.1002/cncr.25750. Epub 2010 Nov 18. Cancer. 2011. PMID: 21656741 Free PMC article.

8

The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy.

Macfarlane R, Heng DY, Xie W, Knox JJ, McDermott DF, Rini BI, Kollmannsberger C, Choueiri TK. Macfarlane R, et al. Cancer. 2012 Jan 15;118(2):365-70. doi: 10.1002/cncr.26201. Epub 2011 Jun 29. Cancer. 2012. PMID: 21717427 Free article.

9

Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions.

Heng DY, Kollmannsberger C, Chi KN. Heng DY, et al. Ther Adv Med Oncol. 2010 Jan;2(1):39-49. doi: 10.1177/1758834009352498. Ther Adv Med Oncol. 2010. PMID: 21789125 Free PMC article.

10

Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma.

Hotte SJ, Bjarnason GA, Heng DY, Jewett MA, Kapoor A, Kollmannsberger C, Maroun J, Mayhew LA, North S, Reaume MN, Ruether JD, Soulieres D, Venner PM, Winquist EW, Wood L, Yong JH, Saad F. Hotte SJ, et al. Curr Oncol. 2011 Oct;18 Suppl 2(Suppl 2):S11-9. Curr Oncol. 2011. PMID: 21969807 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

219 results

Search Page

Filters